KR102455889B1 - 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 - Google Patents

치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Download PDF

Info

Publication number
KR102455889B1
KR102455889B1 KR1020227002513A KR20227002513A KR102455889B1 KR 102455889 B1 KR102455889 B1 KR 102455889B1 KR 1020227002513 A KR1020227002513 A KR 1020227002513A KR 20227002513 A KR20227002513 A KR 20227002513A KR 102455889 B1 KR102455889 B1 KR 102455889B1
Authority
KR
South Korea
Prior art keywords
diamine
fluoro
pyrimidine
benzimidazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227002513A
Other languages
English (en)
Korean (ko)
Other versions
KR20220016305A (ko
Inventor
창선 이
라밀 바이아지토브
리앙시안 카오
토마스 더블유. 데이비스
우 두
롱강 리우
영춘 문
스티븐 디. 페이젯
홍유 렌
나디야 시도렌코
리처드 제랄드 와일드
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Priority to KR1020227035587A priority Critical patent/KR20220143164A/ko
Publication of KR20220016305A publication Critical patent/KR20220016305A/ko
Application granted granted Critical
Publication of KR102455889B1 publication Critical patent/KR102455889B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
KR1020227002513A 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Active KR102455889B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227035587A KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
KR1020217020963A KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020963A Division KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035587A Division KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Publications (2)

Publication Number Publication Date
KR20220016305A KR20220016305A (ko) 2022-02-08
KR102455889B1 true KR102455889B1 (ko) 2022-10-17

Family

ID=50776672

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227035587A Ceased KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227002513A Active KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227035587A Ceased KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Country Status (32)

Country Link
US (3) US10428050B2 (OSRAM)
EP (1) EP2922828B1 (OSRAM)
JP (3) JP6412503B2 (OSRAM)
KR (4) KR102275676B1 (OSRAM)
CN (2) CN111423417B (OSRAM)
AR (1) AR093579A1 (OSRAM)
AU (1) AU2013348009C1 (OSRAM)
BR (1) BR112015011760B1 (OSRAM)
CA (1) CA2892045C (OSRAM)
CL (1) CL2015001377A1 (OSRAM)
CR (1) CR20150294A (OSRAM)
CU (1) CU24387B1 (OSRAM)
DK (1) DK2922828T3 (OSRAM)
EA (2) EA035349B1 (OSRAM)
EC (1) ECSP15019948A (OSRAM)
ES (1) ES2821529T3 (OSRAM)
HK (1) HK1215032A1 (OSRAM)
IL (2) IL238871B (OSRAM)
MA (1) MA38208B1 (OSRAM)
MX (2) MX385385B (OSRAM)
NI (1) NI201500072A (OSRAM)
NZ (2) NZ708909A (OSRAM)
PE (1) PE20151413A1 (OSRAM)
PH (1) PH12015501130B1 (OSRAM)
PL (1) PL2922828T3 (OSRAM)
PT (1) PT2922828T (OSRAM)
SA (1) SA517381847B1 (OSRAM)
SG (2) SG11201503982XA (OSRAM)
TW (1) TWI623531B (OSRAM)
UA (1) UA118094C2 (OSRAM)
WO (1) WO2014081906A2 (OSRAM)
ZA (1) ZA201503642B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623531B (zh) * 2012-11-21 2018-05-11 Ｐｔｃ治療公司 經取代反向嘧啶ｂｍｉ－１抑制劑
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
JP6524094B2 (ja) * 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
EP3335126A4 (en) 2015-08-11 2019-05-01 Cognoa, Inc. METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
US20190016680A1 (en) * 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN110192252A (zh) 2016-11-14 2019-08-30 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
EP3580700A4 (en) * 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US12023335B2 (en) * 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP3911418A1 (en) * 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Method for treating an acute myeloid leukemia
WO2020176610A1 (en) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
BR112021019170A2 (pt) * 2019-03-27 2022-03-03 Ptc Therapeutics Inc Combinações úteis em um método para tratar sarcoma
BR112021019508A2 (pt) * 2019-04-02 2022-02-01 Hinova Pharmaceuticals Inc Composto de amina aromática e uso do mesmo na preparação de reguladores e inibidores duplos de ar e brd4
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069239A1 (en) 2000-12-12 2003-04-10 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (OSRAM) * 1973-09-20 1977-11-30 Delalande Sa
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
IN188411B (OSRAM) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
EP1224185B1 (en) 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
AU4262901A (en) 2000-03-29 2001-10-08 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60136731D1 (de) 2000-09-20 2009-01-08 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1377573B1 (en) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CN100415744C (zh) 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
ATE337312T1 (de) 2001-07-03 2006-09-15 Vertex Pharma Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) * 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
AU2003246100A1 (en) 2002-06-28 2004-01-19 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
EP1713793A4 (en) 2004-02-04 2009-09-02 Smithkline Beecham Corp PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
US20110098301A1 (en) 2005-03-10 2011-04-28 Bayer Healthcare Llc Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
BRPI0713328A2 (pt) 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101679432B (zh) 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
BRPI0720635A2 (pt) 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ATE524459T1 (de) 2007-12-07 2011-09-15 Novartis Ag Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
EP2306836B1 (en) * 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
TW201028399A (en) * 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
MX2011008444A (es) 2009-02-12 2011-09-06 Astellas Pharma Inc Derivado de heteroanillo.
BRPI1013600A2 (pt) 2009-03-27 2019-09-24 Pathway Therapeutics Inc "sulfonamidas de pirimidinila e benzintoazol de 1,3,5-triazinila e seu uso em terapia de câncer"
CA2763624A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2012533551A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピラジン系キナーゼ阻害薬
EP2454257B1 (en) 2009-07-15 2013-08-21 AbbVie Inc. Pyrrolopyridine inhibitors of kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
ES2539170T3 (es) 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
CA2807226A1 (en) * 2010-08-19 2012-02-23 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
PE20131377A1 (es) 2010-09-13 2013-11-30 Novartis Ag Triazina-oxadiazoles
US20140088056A1 (en) * 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2796456A1 (en) * 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
IN2013MN01519A (OSRAM) 2011-02-25 2015-06-12 Yuhan Corp
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
TWI623531B (zh) 2012-11-21 2018-05-11 Ｐｔｃ治療公司 經取代反向嘧啶ｂｍｉ－１抑制劑
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069239A1 (en) 2000-12-12 2003-04-10 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett., 2006, 16, 5973-5977.

Also Published As

Publication number Publication date
CU20150053A7 (es) 2015-11-27
EP2922828A4 (en) 2016-07-27
JP2019031509A (ja) 2019-02-28
MX2015006469A (es) 2015-10-29
KR102356487B1 (ko) 2022-02-08
PE20151413A1 (es) 2015-10-23
IL238871A0 (en) 2015-07-30
CR20150294A (es) 2015-08-20
NZ746607A (en) 2019-11-29
EA201590992A1 (ru) 2015-11-30
US20220064150A1 (en) 2022-03-03
ECSP15019948A (es) 2016-01-29
ES2821529T3 (es) 2021-04-26
CA2892045C (en) 2022-05-31
NI201500072A (es) 2016-01-18
CN111423417B (zh) 2022-11-15
BR112015011760A2 (pt) 2017-07-11
SG11201503982XA (en) 2015-06-29
WO2014081906A3 (en) 2014-07-17
AU2013348009C1 (en) 2019-08-08
CN104918919A (zh) 2015-09-16
CL2015001377A1 (es) 2016-02-19
IL238871B (en) 2019-03-31
JP2020055815A (ja) 2020-04-09
CA2892045A1 (en) 2014-05-30
KR20150086345A (ko) 2015-07-27
EP2922828A2 (en) 2015-09-30
UA118094C2 (uk) 2018-11-26
JP2016504290A (ja) 2016-02-12
BR112015011760B1 (pt) 2022-12-06
EP2922828B1 (en) 2020-07-08
PH12015501130A1 (en) 2015-08-03
US20150315182A1 (en) 2015-11-05
MX2021009892A (es) 2021-09-14
CU24387B1 (es) 2019-03-04
US11180483B2 (en) 2021-11-23
AR093579A1 (es) 2015-06-10
MA38208B1 (fr) 2021-12-31
JP6412503B2 (ja) 2018-10-24
PH12015501130B1 (en) 2023-01-27
EA201890142A1 (ru) 2018-06-29
AU2013348009A1 (en) 2015-06-04
AU2013348009B2 (en) 2018-05-17
KR20220143164A (ko) 2022-10-24
KR20210088740A (ko) 2021-07-14
KR102275676B1 (ko) 2021-07-12
NZ708909A (en) 2019-11-29
PL2922828T3 (pl) 2020-12-28
EA031405B1 (ru) 2018-12-28
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
KR20220016305A (ko) 2022-02-08
TWI623531B (zh) 2018-05-11
US10428050B2 (en) 2019-10-01
TW201427972A (zh) 2014-07-16
DK2922828T3 (da) 2020-08-31
MX385385B (es) 2025-03-18
US20200024260A1 (en) 2020-01-23
EA035349B1 (ru) 2020-05-29
SG10201600149VA (en) 2016-02-26
CN111423417A (zh) 2020-07-17
IL265253A (en) 2019-05-30
PT2922828T (pt) 2020-10-12
HK1215032A1 (zh) 2016-08-12
JP6617186B2 (ja) 2019-12-11
ZA201503642B (en) 2020-10-28
JP6918898B2 (ja) 2021-08-11

Similar Documents

Publication Publication Date Title
KR102455889B1 (ko) 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
US10370371B2 (en) Substituted pyrimidine Bmi-1 inhibitors
US8680113B2 (en) BMI-1 protein expression modulators
US10584115B2 (en) Substituted pyridine and pyrazine BMI-1 inhibitors
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220124

Application number text: 1020217020963

Filing date: 20210705

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220315

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220713

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221013

Application number text: 1020217020963

Filing date: 20210705

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221013

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221013

End annual number: 3

Start annual number: 1

PG1601 Publication of registration